Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Scemblix (asciminib by Year
Scemblix (asciminib — chronic myeloid leukemia Ph+ CML) ($M)
Novartis Scemblix (asciminib: $1,285M in FY2025, up 86.5% from a year earlier.
Latest, FY2025
1,285
Period ended Dec 31, 2025
Change on a year earlier
+86.5%
689 in FY2024
History
5 years
Since FY2021
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| Scemblix | 1 285 | 689 | 87 | 85”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Scemblix (asciminib — chronic myeloid leukemia Ph+ CML) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,285 | +86.5% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 689 | +66.8% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 413 | +177.2% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 149 | +2,028.6% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | 7 | – | Novartis Form 6-K (0001370368-23-000008) ↗ |
Breakdown
What makes up scemblix (asciminib
Cite this data
StockData. (2026). Novartis Scemblix (asciminib ($M), annual FY2021–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-scemblix
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.